Shortly after selling Sierra to GSK, Stephen Dilly heads to enzyme engineer Codexis as new CEO

On Feb. 22, Stephen Dilly had no clear ambitions of selling Sierra Oncology to GSK. But that quickly changed over the subsequent weeks, and since selling the biotech for nearly $2 billion in the spring, he’s made a quick leap to another company’s C-suite.